Recent therapeutic advances with tyrosine-kinase inhibitors in nonsmall-cell lung cancer

Hot topics
Chairs: J-P. Sculier (Brussels, Belgium), R. M. Huber (Munich, Germany)
Aims: The audience will learn about the emergence of a new type of drug, the tyrosine-kinase inhibitors (TKI), in the management of lung cancer and the most recent clinical applications of TKI in the management of some advanced nonsmall cell lung cancer (NSCLC).

TKIs: a new class of drugs in the management of lung cancer J. Cadranel (Paris, France)
Maintenance treatment with erlotinib after induction chemotherapy for advanced NSCLC B. Coudert (Dijon, France)
ALK inhibition with crizotinib J. Clark (Boston, United States of America)